TriangleHEALTH PROFESSIONAL · SOURCE READING
Monoclonal antibody targeting of amyloid deposits
Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
The monoclonal antibody anselamimab binds to immunoglobulin-associated amyloid in an effort to promote phagocytosis and clearance of the amyloid deposits.
In a phase I study (NCT02245867), 27 patients with deep hematologic responses to myeloma therapy, but persistent organ involvement, received anselamimab.[35]This treatment is not approved by the U.S. Food and Drug Administration and is under clinical evaluation.[35][Level of evidence C3]
Source links and citations
In a phase I study (NCT02245867), 27 patients with deep hematologic responses to myeloma therapy, but persistent organ involvement, received anselamimab.[35]This treatment is not approved by the U.S. Food and Drug Administration and is under clinical evaluation.[35][Level of evidence C3]
Fifteen of 24 patients (63%) manifested cardiac, renal, hepatic, gastrointestinal, or soft tissue response by serum biomarkers (such as NT-proBNP), renal function, cardiac function, or imaging studies.
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice